Germany’s Stade Arzneimittel (SAZ: Xetra) is now contributing to the care of chronic pain patients in particular with medical cannabis, offering a complementary therapy option, as today it announced the launch of a medical cannabis product under the trade name CannabiStada.
STADAPHARM GmbH, which is responsible for the specialty business of the Stada Group and has many years of experience in pain therapy, is now introducing its own product portfolio for this new form of therapy. Therapy with medical cannabis is primarily directed at chronic pain patients for whom established medications, such as with opioids, do not achieve satisfactory therapeutic success. Furthermore, medical cannabis can also be used for patients with spasticity in multiple sclerosis and other neurological and oncological therapy fields.
“Stada is one of the first leading pharmaceutical manufacturers to expand its portfolio with medical cannabis in Germany. In doing so, we are benefiting from our expertise in the field of specialty pharmaceuticals and are complementing this with a modern portfolio of patient-specific therapies,” explains Stada chief executive Peter Goldschmidt.
With this novel therapy option, Stada says it is strengthening its perception as a “Go-To-Partner” for doctors and pharmacists. In addition to support for current research and patient experience with medical cannabis, orientation in the prescription and reimbursement process is also to be created. In order to improve access to medical cannabis and its therapeutic benefits, Stada is committed to simplifying cannabis prescription.
Partnered with MediPharma
Last October, Stada signed a partnership with Canada’s MediPharm, forging the way as a large pharmaceutical company commercializing medical cannabis products.
At that time, the Medical Cannabis Network reported the medical cannabis market in Germany was valued at between 150 million euros ($179 million) and 175 million euros, despite only around 10% of the 20,000 pharmacies in Germany selling medical cannabis products.